KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Jazz Pharmaceuticals (JAZZ) Shares Repurchased (2016 - 2024)

Jazz Pharmaceuticals has reported Shares Repurchased over the past 10 years, most recently at $150.0 million for Q3 2024.

Quarterly Shares Repurchased rose 101.69% to $150.0 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $150.0 million through Dec 2025, down 53.73% year-over-year, with the annual reading at $125.0 million for FY2025, 59.86% down from the prior year.
Shares Repurchased was $150.0 million for Q3 2024 at Jazz Pharmaceuticals, up from $99.8 million in the prior quarter.
Over five years, Shares Repurchased peaked at $150.0 million in Q3 2024 and troughed at $7.5 million in Q2 2020.
The 3-year median for Shares Repurchased is $99.8 million (2023), against an average of $94.1 million.
Biggest five-year swings in Shares Repurchased: crashed 87.5% in 2020 and later surged 101.69% in 2024.
Tracing JAZZ's Shares Repurchased over 3 years: stood at $7.5 million in 2020, then surged by 1233.44% to $99.8 million in 2023, then soared by 50.31% to $150.0 million in 2024.
According to Business Quant data, Shares Repurchased over the past three periods came in at $150.0 million, $99.8 million, and $74.4 million for Q3 2024, Q4 2023, and Q3 2023 respectively.